498 related articles for article (PubMed ID: 34416294)
1. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C; Cork MJ; Ardern-Jones MR; Eichenfield LF; Barbarot S; Feeney C; Rojo R; Lazariciu I; Nesnas J
J Dermatolog Treat; 2023 Dec; 34(1):2200866. PubMed ID: 37036183
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
4. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
6. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
7. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
11. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
[TBL] [Abstract][Full Text] [Related]
12. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
14. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
[TBL] [Abstract][Full Text] [Related]
16. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
Zheng H; Chen Y; Xu Y; Deng X
Eur J Dermatol; 2023 Oct; 33(5):530-543. PubMed ID: 38297930
[TBL] [Abstract][Full Text] [Related]
18. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
20. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
